Cipla Limited
CIPLA
Rank in Stocks
#1817
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Share Price
$14.63
Last synced: 2026-10-16
Market Cap
$11.82B
Change (1 day)
0.39%
Change (1 year)
-18.37%
Country
IN
Trade Cipla Limited (CIPLA)
Category
Healthcare
EPS for Cipla Limited (CIPLA)
EPS as of June 2026 TTM: $0.46
According to Cipla Limited latest financial reports and stock price the company's current EPS (TTM) is $0.46. At the end of 2024 the company had a EPS of $0.61 an increase over its 2023 EPS that were of $0.42.
EPS history for Cipla Limited from 2004 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.46 | -39.39% |
| 2025 | $0.76 | 24.70% |
| 2024 | $0.61 | 44.90% |
| 2023 | $0.42 | 2.80% |
| 2022 | $0.41 | 0.88% |
| 2021 | $0.41 | 59.95% |
| 2020 | $0.25 | -6.77% |
| 2019 | $0.27 | 1.49% |
| 2018 | $0.27 | 39.41% |
| 2017 | $0.19 | -24.42% |
| 2016 | $0.26 | 8.40% |
| 2015 | $0.24 | -18.30% |
| 2014 | $0.29 | -18.53% |
| 2013 | $0.35 | 26.01% |
| 2012 | $0.28 | 1.66% |
| 2011 | $0.28 | -9.38% |
| 2010 | $0.31 | 56.09% |
| 2009 | $0.20 | -13.31% |
| 2008 | $0.23 | 13.49% |
| 2007 | $0.20 | 9.18% |
| 2006 | $0.18 | 45.52% |
| 2005 | $0.13 | 37.67% |
| 2004 | $0.09 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | 20.78% |
IN
|
